Oppenheimer Reiterates Outperform, Raises PT to $33 on ViroPharma

Oppenheimer maintains its Outperform rating on ViroPharma VPHM as new Vancocin label provides three years of exclusivity. Oppenheimer says, “Modernization of Vancocin Label Likely to Provide Three-Year Exclusivity. Vancocin's modernized label includes updated safety/efficacy data related to treating C. difficile. As such, we believe Vancocin meets requirements for exclusivity beginning today (anticipate FDA confirmation during 1Q12) through YE2014, quelling concerns of a generic Vancocin entrant which was largely expected to occur during 2012.” VPHM closed at $27.80 per share on Wednesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: Analyst ColorPrice TargetPre-Market OutlookAnalyst RatingsOppenheimer
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!